

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for June 2023

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Eltrombopag	Revolade	ELTROMBOPAG OLAMINE	25 mg	tablet	02506742
Apotex Inc.	Apo-Eltrombopag	Revolade	ELTROMBOPAG OLAMINE	50 mg	tablet	02506769
Apotex Inc.	Apo-Bromfenac	Prolensa	BROMFENAC	0.07% w/v	solution, (ophthalmic, topical)	02537788
Mint Pharmaceuticals Inc.	Mint-Clonidine	Dixarit	CLONIDINE HCl	0.025 mg	tablet	02534738
Pharmaris Canada Inc.	PRZ-Metformin	Glucophage	METFORMIN HCl	850 mg	tablet	02531909